Derangements of intravascular remodeling of lipoproteins in type 2 diabetes mellitus: Consequences for atherosclerosis development

详细信息    查看全文

• 作者：Geesje M. Dallinga-Thie (1)
  Robin P. F. Dullaart
  Arie van Tol
  
• 刊名：Current Diabetes Reports
• 出版年：2008
• 出版时间：February 2008
• 年：2008
• 卷：8
• 期：1
• 页码：65-70
• 全文大小：145KB
• 参考文献：1. Taskinen MR: plus-plus">Diabetic dyslipidaemia: from basic research to clinical practice. / Diabetologia 2003, plus-plus">46:733-49. f="http://dx.doi.org/10.1007/s00125-003-1111-y">CrossRef
  2. Ginsberg HN: plus-plus">Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. / J Clin Endocrinol Metab 2006, plus-plus">91:383-92. f="http://dx.doi.org/10.1210/jc.2005-2084">CrossRef
  3. Hokanson JE, Austin MA: plus-plus">Plasma triglyceride is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol: a meta analyses of population based prospective studies. / J Cardiovasc Res 1996, plus-plus">3:213-19. f="http://dx.doi.org/10.1097/00043798-199604000-00014">CrossRef
  4. Nordestgaard BG, Benn M, Schnohr P, et al.: plus-plus">Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. / J Am Med Ass 2007, plus-plus">298:299-08. f="http://dx.doi.org/10.1001/jama.298.3.299">CrossRef
  5. Bansal S, Buring JE, Rifai N, et al.: plus-plus">Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. / J Am Med Assoc 2007, plus-plus">298:309-16. f="http://dx.doi.org/10.1001/jama.298.3.309">CrossRef
  6. Eckel RH: plus-plus">Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVD. / Proc Nutr Soc 2007, plus-plus">66:82-5. f="http://dx.doi.org/10.1017/S0029665107005320">CrossRef
  7. Reaven GM: plus-plus">Metabolic syndrome. Pathophysiology and implications for management of cardiovascular disease. / Circulation 2002, plus-plus">106:286-88. f="http://dx.doi.org/10.1161/01.CIR.0000019884.36724.D9">CrossRef
  8. Rader DJ: plus-plus">Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. / Am J Med 2007, plus-plus">120:S12–S18. f="http://dx.doi.org/10.1016/j.amjmed.2007.01.003">CrossRef
  9. Barter P: plus-plus">Managing diabetic dyslipidaemia—beyond LDL-C: HDL-C and triglycerides. / Atheroscler Suppl 2006, plus-plus">7:17-1. f="http://dx.doi.org/10.1016/j.atherosclerosissup.2006.05.003">CrossRef
  10. Kontush A, Chapman MJ: plus-plus">Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. / Pharmacol Rev 2006, plus-plus">58:342-74. f="http://dx.doi.org/10.1124/pr.58.3.1">CrossRef
  11. Lewis GF, Carpentier A, Adeli K, et al.: plus-plus">Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. / Endocr Rev 2002, plus-plus">23:201-29. f="http://dx.doi.org/10.1210/er.23.2.201">CrossRef
  12. Frayn KN, Fielding BA, Karpe F: plus-plus">Adipose tissue fatty acid metabolism and cardiovascular disease. / Curr Opin Lipidol 2005, plus-plus">16:409-15. f="http://dx.doi.org/10.1097/01.mol.0000171919.62129.6b">CrossRef
  13. Adiels M, Taskinen MR, Packard C, et al.: plus-plus">Overproduction of large VLDL particles is driven by increased liver fat content in man. / Diabetologia 2006, plus-plus">49:755-65. f="http://dx.doi.org/10.1007/s00125-005-0125-z">CrossRef
  14. Eriksson JW, Buren J, Svensson M, et al.: plus-plus">Postprandial regulation of blood lipids and adipose tissue lipoprotein lipase in type 2 diabetes patients and healthy control subjects. / Atherosclerosis 2003, plus-plus">166:359-67. f="http://dx.doi.org/10.1016/S0021-9150(02)00366-0">CrossRef
  15. Shimizugawa T, Ono M, Shimamura M, et al.: plus-plus">ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. / J Biol Chem 2002, plus-plus">277:33742-3748. f="http://dx.doi.org/10.1074/jbc.M203215200">CrossRef
  16. Dallinga-Thie GM, Dullaart RP, van Tol A: plus-plus">Concerted actions of cholesteryl ester transfer protein and phospholipid transfer protein in type 2 diabetes: effects of apolipoproteins. / Curr Opin Lipidol 2007, plus-plus">18:251-57. f="http://dx.doi.org/10.1097/MOL.0b013e3280e12685">CrossRef
  17. Barter PJ, Brewer HB, Jr, Chapman MJ, et al.: plus-plus">Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. / Arterioscler Thromb Vasc Biol 2003, plus-plus">23:160-67. f="http://dx.doi.org/10.1161/01.ATV.0000054658.91146.64">CrossRef
  18. Vaisar T, Pennathur S, Green PS, et al.: plus-plus">Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. / J Clin Invest 2007, plus-plus">117:746-56. f="http://dx.doi.org/10.1172/JCI26206">CrossRef
  19. Rezaee F, Casetta B, Levels JH, et al.: plus-plus">Proteomic analysis of high-density lipoprotein. / Proteomics 2006, plus-plus">6:721-30. f="http://dx.doi.org/10.1002/pmic.200500191">CrossRef
  20. Nobecourt E, Jacqueminet S, Hansel B, et al.: plus-plus">Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. / Diabetologia 2005, plus-plus">48:529-38. f="http://dx.doi.org/10.1007/s00125-004-1655-5">CrossRef
  21. Schaefer EJ, Asztalos BF: plus-plus">Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. / Curr Opin Lipidol 2006, plus-plus">17:394-98. f="http://dx.doi.org/10.1097/01.mol.0000236364.63840.d8">CrossRef
  22. Miida T, Miyazaki O, Nakamura Y, et al.: plus-plus">Analytical performance of a sandwich enzyme immunoassay for pre beta 1-HDL in stabilized plasma. / J Lipid Res 2003, plus-plus">44:645-50. f="http://dx.doi.org/10.1194/jlr.D200025-JLR200">CrossRef
  23. Kruijt JK, Groen AK, Van Berkel TJ, et al.: plus-plus">Emerging roles of the intestine in control of cholesterol metabolism. / World J Gastroenterol 2007, plus-plus">12:6429-439.
  24. Tall AR: plus-plus">An overview of reverse cholesterol transport. / Eur Heart J 1998, plus-plus">19(Suppl A):A31–A35.
  25. Barter P: plus-plus">The inflammation: lipoprotein cycle. / Atheroscler Suppl 2005, plus-plus">6:15-0. f="http://dx.doi.org/10.1016/j.atherosclerosissup.2005.02.004">CrossRef
  26. Navab M, Imes SS, Hama SY, et al.: plus-plus">Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. / J Clin Invest 1991, plus-plus">88:2039-046. f="http://dx.doi.org/10.1172/JCI115532">CrossRef
  27. Lusis AJ: plus-plus">Atherosclerosis. / Nature 2000, plus-plus">407:233-41. f="http://dx.doi.org/10.1038/35025203">CrossRef
  28. Goldberg IJ, Dansky HM: plus-plus">Diabetic vascular disease: an experimental objective. / Arterioscler Thromb Vasc Biol 2006, plus-plus">26:1693-701. f="http://dx.doi.org/10.1161/01.ATV.0000231521.76545.f6">CrossRef
  29. Nobecourt E, Davies MJ, Brown BE, et al.: plus-plus">The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. / Diabetologia 2007, plus-plus">50:643-53. f="http://dx.doi.org/10.1007/s00125-006-0574-z">CrossRef
  30. Hoang A, Murphy AJ, Coughlan MT, et al.: plus-plus">Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. / Diabetologia 2007, plus-plus">50:1770-779. f="http://dx.doi.org/10.1007/s00125-007-0718-9">CrossRef
  31. Curtiss LK, Witztum JL: plus-plus">Plasma apolipoproteins AI, AII, B, CI, and E are glucosylated in hyperglycemic diabetic subjects. / Diabetes 1985, plus-plus">34:452-61. f="http://dx.doi.org/10.2337/diabetes.34.5.452">CrossRef
  32. Brown BE, Rashid I, Van Reyk DM, et al.: plus-plus">Glycation of low-density lipoprotein results in the time-dependent accumulation of cholesteryl esters and apolipoprotein B-100 protein in primary human monocyte-derived macrophages. / FEBS J 2007, plus-plus">274:1530-541. f="http://dx.doi.org/10.1111/j.1742-4658.2007.05699.x">CrossRef
  33. Ikonen E:plus-plus">Mechanisms for cellular cholesterol transport: defects and human disease. / Physiol Rev 2006, plus-plus">86:1237-261.
  34. Oram JF, Heinecke JW: plus-plus">ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. / Physiol Rev 2005, plus-plus">85:1343-372. f="http://dx.doi.org/10.1152/physrev.00005.2005">CrossRef
  35. Duong M, Collins HL, Jin W, et al.: plus-plus">Relative contributions of ABCA1 and SR-BI to cholesterol efflux to serum from fibroblasts and macrophages. / Arterioscler Thromb Vasc Biol 2006, plus-plus">26:541-47. f="http://dx.doi.org/10.1161/01.ATV.0000203515.25574.19">CrossRef
  36. Attie AD: plus-plus">ABCA1: at the nexus of cholesterol, HDL and atherosclerosis. / Trends Biochem Sci 2007, plus-plus">32:172-79. f="http://dx.doi.org/10.1016/j.tibs.2007.02.001">CrossRef
  37. Gelissen IC, Harris M, Rye KA, et al.: plus-plus">ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. / Arterioscler Thromb Vasc Biol 2006, plus-plus">26:534-40. f="http://dx.doi.org/10.1161/01.ATV.0000200082.58536.e1">CrossRef
  38. Vaughan AM, Oram JF: plus-plus">ABCG1 redistributes cell cholesterol to domains removable by high density lipoprotein but not by lipid-depleted apolipoproteins. / J Biol Chem 2005, plus-plus">280:30150-0157. f="http://dx.doi.org/10.1074/jbc.M505368200">CrossRef
  39. Brooks-Wilson A, Marcil M, Clee SM, et al.: plus-plus">Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. / Nat Genet 1999, plus-plus">22:336-45. f="http://dx.doi.org/10.1038/11905">CrossRef
  40. Marcil M, Brooks-Wilson A, Clee SM, et al.: plus-plus">Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. / Lancet 1999, plus-plus">354:1341-346. f="http://dx.doi.org/10.1016/S0140-6736(99)07026-9">CrossRef
  41. Vedhachalam C, Duong PT, Nickel M, et al.: plus-plus">Mechanism of ATP-binding cassette transporter AI (ABCA1)-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. / J Biol Chem 2007, plus-plus">282:25123-5130. f="http://dx.doi.org/10.1074/jbc.M704590200">CrossRef
  42. Wang N, Tall AR: plus-plus">Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. / Arterioscler Thromb Vasc Biol 2003, plus-plus">23:1178-184. f="http://dx.doi.org/10.1161/01.ATV.0000075912.83860.26">CrossRef
  43. Yancey PG, Bortnick AE, Kellner-Weibel G, et al.: plus-plus">Importance of different pathways of cellular cholesterol efflux. / Arterioscler Thromb Vasc Biol 2003, plus-plus">23:712-19. f="http://dx.doi.org/10.1161/01.ATV.0000057572.97137.DD">CrossRef
  44. Wang MD, Franklin V, Marcel YL: plus-plus">In vivo reverse cholesterol transport from macrophages lacking ABCA1 expression is impaired. / Arterioscler Thromb Vasc Biol 2007, plus-plus">27:1837-842. f="http://dx.doi.org/10.1161/ATVBAHA.107.146068">CrossRef
  45. Wang N, Lan D, Chen W, et al.: plus-plus">ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. / Proc Natl Acad Sci U S A 2004, plus-plus">101:9774-779. f="http://dx.doi.org/10.1073/pnas.0403506101">CrossRef
  46. Wang X, Collins HL, Ranalletta M, et al.: plus-plus">Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. / J Clin Invest 2007, plus-plus">117:2216-224. f="http://dx.doi.org/10.1172/JCI32057">CrossRef
  47. Vergeer M, Hovingh GK, Vissers MN, et al.: plus-plus">Heterozygosity for a mutation in the extracellular domain of SR-B1 is associated with high HDL cholesterol levels in a family of Caucasian descent. / Circulation 2006, plus-plus">115:abstract 1340.
  48. Fielding CJ, Fielding PE: plus-plus">Molecular physiology of reverse cholesterol transport. / J Lipid Res 1995, plus-plus">36:211-28.
  49. Clark RW, Ruggeri RB, Cunningham D, et al.: plus-plus">Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. / J Lipid Res 2006, plus-plus">47:537-52. f="http://dx.doi.org/10.1194/jlr.M500349-JLR200">CrossRef
  50. Jauhiainen M, Metso J, Pahlman R, et al.: plus-plus">Human plasma phospholipid transfer protein causes high density lipoprotein conversion. / J Biol Chem 1993, plus-plus">268:4032-036.
  51. Von Eckardstein A, Jauhiainen M, Huang YD, et al.: plus-plus">Phospholipid transfer protein mediated conversion of high density lipoproteins generates b1-HDL. / Biochim Biophys Acta 1996, plus-plus">1301:255-62.
  52. Guerin M, Le Goff W, Lassel TS, et al.: plus-plus">Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. / Arterioscler Thromb Vasc Biol 2001, plus-plus">21:282-88.
  53. de Vries R, Borggreve SE, Dullaart RPF: plus-plus">Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. / Clin Lab 2003, plus-plus">49:601-13.
  54. Bhatnagar D, Durrington PN, Kumar S, et al.: plus-plus">Plasma lipoprotein composition and cholesteryl ester transfer from high density lipoproteins to very low density and low density lipoproteins in patients with non-insulin-dependent diabetes mellitus. / Diabet Med 1996, plus-plus">13:139-44. f="http://dx.doi.org/10.1002/(SICI)1096-9136(199602)13:2<139::AID-DIA15>3.0.CO;2-C">CrossRef
  55. de Vries R, Perton FG, Dallinga-Thie GM, et al.: plus-plus">Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. / Diabetes 2005, plus-plus">54:3554-559. f="http://dx.doi.org/10.2337/diabetes.54.12.3554">CrossRef
  56. Desrumaux C, Athias A, Bessède G, et al.: plus-plus">Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. / Arterioscler Thromb Vasc Biol 1999, plus-plus">19:266-75.
  57. Riemens SC, van Tol A, Sluiter WJ, et al.: plus-plus">Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese type II diabetic patients. / Diabetologia 1998, plus-plus">41:929-34. f="http://dx.doi.org/10.1007/s001250051009">CrossRef
  58. Tan KC, Shiu SW, Wong Y, et al.: plus-plus">Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. / Atherosclerosis 2005, plus-plus">178:365-70. f="http://dx.doi.org/10.1016/j.atherosclerosis.2004.09.005">CrossRef
  59. de Vries R, Groen AK, Perton FG, et al.: plus-plus">Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterification. / Atherosclerosis 2007, [Epub ahead of print.]
  60. Hirayama S, Miida T, Miyazaki O, et al.: plus-plus">Pre beta1-HDL concentration is a predictor of carotid atherosclerosis in type 2 diabetic patients. / Diabetes Care 2007, plus-plus">30:1289-291. f="http://dx.doi.org/10.2337/dc06-1948">CrossRef
  61. Chetiveaux M, Lalanne F, Lambert G, et al.: plus-plus">Kinetics of prebeta1 HDL and alphaHDL in type II diabetic patients. / Eur J Clin Invest 2006, plus-plus">36:29-4. f="http://dx.doi.org/10.1111/j.1365-2362.2006.01586.x">CrossRef
  62. Dullaart RPF, van Tol A: plus-plus">Role of phospholipid transfer protein and prebeta-high density lipoproteins in maintaining cholesterol efflux from Fu5AH cells to plasma from insulin-resistant subjects. / Scand J Clin Lab Invest 2001, plus-plus">61:69-4. f="http://dx.doi.org/10.1080/00365510151068027">CrossRef
  63. Watanabe H, Soderlund S, Soro-Paavonen A, et al.: plus-plus">Decreased high-density lipoprotein (HDL) particle size, prebeta-, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness. / Arterioscler Thromb Vasc Biol 2006, plus-plus">26:897-02. f="http://dx.doi.org/10.1161/01.ATV.0000209577.04246.c0">CrossRef
  
• 作者单位：Geesje M. Dallinga-Thie (1)
  Robin P. F. Dullaart
  Arie van Tol
  
  1. Laboratory of Experimental Vascular Medicine G1-113, Academic Medical Center Amsterdam, PO Box 22660, 1100DD, Amsterdam, the Netherlands
  

文摘

In type 2 diabetes mellitus, elevated fasting and postprandial plasma triglycerides, small dense low-density lipoprotein particles, low high-density lipoprotein (HDL) cholesterol levels, and increased action of lipid transfer proteins may enhance peripheral lipid accumulation and increase cardiovascular risk. Despite low HDL cholesterol, plasma’s ability to stimulate cellular cholesterol efflux, reflecting an early step in the reverse cholesterol transport pathway, appears to be maintained, perhaps implicating a compensatory mechanism.